Veru (NASDAQ:VERU) Raised to Hold at Wall Street Zen

Veru (NASDAQ:VERU) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Several other research firms have also issued reports on VERU. Canaccord Genuity Group restated a “buy” rating and set a $25.00 price target on shares of Veru in a report on Thursday, June 4th. Weiss Ratings lowered shares of Veru from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $24.50.

Veru Stock Performance

NASDAQ VERU opened at $2.41 on Friday. The business’s 50-day moving average price is $2.49 and its two-hundred day moving average price is $2.52. Veru has a 12 month low of $2.05 and a 12 month high of $7.33. The firm has a market capitalization of $41.09 million, a PE ratio of -3.49 and a beta of -1.17.

Veru (NASDAQ:VERU) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.02. As a group, analysts forecast that Veru will post -1.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Veru

Several institutional investors and hedge funds have recently made changes to their positions in the business. Royal Bank of Canada lifted its stake in shares of Veru by 69.3% in the first quarter. Royal Bank of Canada now owns 12,239 shares of the company’s stock valued at $27,000 after buying an additional 5,008 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of Veru during the first quarter worth about $153,000. Finally, FNY Investment Advisers LLC acquired a new stake in shares of Veru in the 2nd quarter worth about $328,000. Institutional investors own 47.16% of the company’s stock.

Veru Company Profile

Veru Inc is a biopharmaceutical company focused on developing medicines for obesity, metabolic disorders and cancer. Its development programs are designed to address weight management, preservation of muscle mass during weight loss and treatment of certain hormone-sensitive cancers.

The company’s lead investigational product, enobosarm, is an oral selective androgen receptor modulator being evaluated for its potential to promote or preserve lean muscle while supporting weight loss. Veru has also developed oncology candidates, including sabizabulin, an oral microtubule disruptor studied in cancer indications, and other hormone-directed therapies.

Veru was formerly known as The Female Health Company and historically developed and commercialized the FC2 Female Condom, a female-controlled barrier contraceptive and sexually transmitted infection prevention product distributed in the United States and international markets.